Actively Recruiting
Efficacy and Safety of Different Initial Doses of Oral Propranolol in the Treatment of Ulcerated Infantile Hemangioma
Led by West China Hospital · Updated on 2026-03-16
40
Participants Needed
1
Research Sites
65 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The main objective of this study was to determine the efficacy of different doses of propranolol in the treatment of ulcerattion infantile hemangioma (IH).
CONDITIONS
Official Title
Efficacy and Safety of Different Initial Doses of Oral Propranolol in the Treatment of Ulcerated Infantile Hemangioma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- All patients with ulcerated infantile hemangioma
- Children with ulcerated infantile hemangioma treated with propranolol
You will not qualify if you...
- Children with ulcerated infantile hemangioma who received other treatments
- Families who refused to participate
- Patients with contraindications to propranolol such as allergy, severe slow heart rate, or bronchial asthma
- Children lost to follow-up during propranolol treatment
- Children unable to take or continue propranolol for other reasons
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
West China Hospital of Sichuan University
Chengdu, Sichuan, China, 610041
Actively Recruiting
Research Team
Y
Yi Ji
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here